Genmab A/S ADR (GMAB) Stock Price, Quote & News

Company Profile

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R...

Industry: Biotechnology

Sector: Healthcare

Phone: 45 70 20 27 28

Website: www.genmab.com

Address:

Carl Jacobsens Vej 30, Valby, Copenhagen, Denmark

CaptainAmrica Sep. 18 at 2:02 PM

$ASND $GMAB . Sold for a little gain.

0 · Reply

Quantumup Sep. 10 at 2:29 PM

Cantor reiterated $BCAX at Overweight and said -- We continue to believe that BCAX shares remain meaningfully undervalued given ficerafusp's potential to address the large and underserved HPV-negative HNSCC market. MRUS - $GMAB $JNJ PYXS MRK BMY LLY Cantor added—The company's $1B EV is well below the $8B GMAB (NC) paid for competitor MRUS last fall, and our $1.5B peak sales forecast in 1L R/M HPV-negative HNSCC supports severalfold upside from current levels. We believe growing anticipation of the mid-2027 Phase 3 interim results could drive continued share appreciation.

0 · Reply

Quantumup Sep. 10 at 11:32 AM

H.C. Wainwright⬆️ $PYXS to $8 from $7; reit'd Buy ~updated data from Ph1 monoTx study of MICVO in 2L+ R/M HNSCC supports broad coverage $GMAB $BCAX MRK Wells Fargo⬆️Pyxis' PT to $19 from $12; reit'd OW ~sees MICVO as Key 2L+ option—ests $2B peak Wedbush⬆️Pyxis' PT to $8 from $6; reit'd OP Here's what Wells Fargo and Wedbush had to say: https://x.com/Quantumup1/status/2098011386181738898?s=20

0 · Reply

FiveMinute Sep. 3 at 9:27 PM

$GMAB 🟢 $GMAB pushing further into a solid uptrend — 5% above EMA20, RSI 67.6, biotech name that just dropped new oncology data on its bispecific antibody pipeline. Structure's clean underneath (EMA20 > EMA50 > EMA200), but momentum's getting a little stretched for my taste at these levels. Not financial advice, just flagging what my screener's picking up. Anyone following Genmab's pipeline closely?

0 · Reply

SilverEagle Sep. 2 at 12:41 PM

$GMAB watching over 36

0 · Reply

izjustlooking Sep. 2 at 9:01 AM

$GMAB 16h ago. Deutsche Bank analyst Emmanuel Papadakis raised the firm’s price target on Genmab ($GMAB) to DKK 2,500 from DKK 2,250 and keeps a Buy rating on the shares. That's $387. Added

0 · Reply

FiveMinute Aug. 27 at 9:13 PM

🎯 $GMAB — Continuation setup, up to +10% to target ($37.51) BB_RANK 57/100 | Fundamentals 60/100 | +6.18% above EMA20 Detected 8/27, present 4 of last 5 sessions. Support: $31.59 | Resistance: $34.68 TP1: $35.80 (+5%) | TP2: $37.51 (+10%) Status: EN OBSERVATION Not financial advice.

0 · Reply

FiveMinute Aug. 26 at 9:12 PM

$GMAB 📈 Automated swing setup flagged tonight (8/26)! Appeared in 4 of the last 5 sessions.🔥 CONTINUATION setup• Ref Price: $33.75• Price +5.78% above EMA20 ($31.91)• RSI: 68.1 (neutral-high, strong momentum)• Volume: 3.09M (105% of avg • Moderate)• Scores: BB_RANK 56.5/100 | Fund. 60/100 | Tech. 55/100🎯 Key Levels to watch:• Targets: $35.44 (TP1) / $37.12 (TP2)• Resistance: $33.96• Support / Interest Zone: $31.59 – $32.33• Invalidation (SL): $32.06STATUS: EN OBSERVATION 👀 Healthy bullish alignment above key EMAs. Watch for a potential healthy retest of the EMA20 interest zone or a clean breakout past resistance.What's the play here, bulls? 🚀 #SwingTrading #TechnicalAnalysis #Biotech Not financial advice.

0 · Reply

JuggernautRaider Aug. 26 at 8:46 PM

$TNXP who cares about money when we have human brothers and sisters whose souls are burning in Hell right now? We can unleash them. How about Psalm 41? Who needs some healing? Click this link for some beautiful healing scripture 📕 🙏 💚 https://www.biblegateway.com/passage/?search=Psalm%2041&version=NIV $ALT $CCCC $GMAB why not?

0 · Reply

WallStJesus Aug. 25 at 7:25 PM

$GMAB

0 · Reply

Genmab Transcript: Morgan Stanley 24th Annual Global Healthcare Conference

2026-09-11T17:00:25.000Z - 7 days ago

Genmab A/S (CPH:GEN) -- Oncology Innovation and Growth | Artisan International Small-Mid Fund ...

Sep 9, 2026, 3:00 PM EDT - 9 days ago

Genmab Transcript: Wells Fargo 21st Annual Healthcare Conference

Sep 8, 2026, 2:44 PM EDT - 10 days ago

Market Cap	21.54B
Revenue (ttm)	3.72B
Net Income (ttm)	963.00M
EPS (ttm)	N/A
PE Ratio	24.75
Forward PE	28.15
Profit Margin	25.89%
Debt to Equity Ratio	0.86

Volume	2,711,500
Avg Vol	2,346,436
Day's Range	N/A - N/A
Shares Out	623.78M
Stochastic %K	86%
Beta	0.84
Analysts	Strong Sell
Price Target	$38.60